journal article·2012-01

Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome

Xiyang Sun, Zhiqing Pang, Hongxing Ye, Bo Qiu, Liangran Guo, Jingwei Li, Jinfeng Ren, Yong Qian, Qizhi Zhang, Jun Chen, Xinguo Jiang

Biomaterials· Volume 33· Issue 3
Publisher page

Abstract

In this study, we report an angiopep-2 modified cationic liposome (ANG-CLP) for the efficient co-delivery of a therapeutic gene encoding the human tumour necrosis factor-related apoptosis-inducing ligand (pEGFP-hTRAIL) and paclitaxel (PTX) to glioma. The dual targeting co-delivery system (ANG-CLP/PTX/pEGFP-hTRAIL) improved uptake and gene expression not only in U87 MG cells and BCECs, but also in the glioma bed and infiltrating margin of intracranial U87 MG glioma-bearing models. The system selectively induces apoptosis in U87 MG cells while reducing toxicity to BCECs. The results of the pharmacodynamics studies showed that the apoptosis of glioma cells in in vitro BBB models and in U87 MG glioma-bearing mice induced by ANG-CLP/PTX/pEGFP-hTRAIL was more apparent and widespread than that induced by single medication systems and unmodified co-delivery system. More importantly, the median survival time of brain tumour-bearing mice treated with ANG-CLP/PTX/pEGFP-hTRAIL was 69.5 days, significantly longer than that of other groups, even longer than the commercial temozolomide group (47 days). Therefore, the dual targeting co-delivery system is a promising drug delivery strategy against glioma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Cell death mechanisms and regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. Cancer drug resistance: the central role of the karyotype10.1016/j.drup.2007.02.003 ↗
2. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer10.1038/nmat1737 ↗
3. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect10.1016/j.biomaterials.2009.03.006 ↗
4. TRAIL and apoptosis induction by TNF-family death receptors10.1038/sj.onc.1207232 ↗
5. TRAIL and malignant glioma10.1016/S0083-6729(04)67022-1 ↗
6. TNF-alpha- and TRAIL-resistant glioma cells undergo autophagy-dependent cell death induced by activated microglia10.1002/glia.20785 ↗
7. TRAIL and chemotherapeutic drugs in cancer therapy10.1016/S0083-6729(04)67019-1 ↗
8. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells10.1158/1535-7163.MCT-09-0415 ↗
9. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo10.1038/5517 ↗
10. Angiogenesis in brain tumours10.1038/nrn2175 ↗
11. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?10.1016/j.drudis.2008.09.005 ↗
12. Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma10.1023/B:NEON.0000003655.03671.fa ↗
13. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer10.1016/j.biomaterials.2010.09.070 ↗
14. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers10.1016/j.biomaterials.2009.11.077 ↗
15. A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex10.1021/mp800177f ↗
16. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model10.1158/0008-5472.CAN-04-1683 ↗
17. Non-immunostimulatory nonviral vectors10.1096/fj.04-2187fje ↗
18. Non-viral gene delivery with cationic liposome-DNA complexes10.1007/978-1-59745-237-3_10 ↗
19. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer10.1016/j.biomaterials.2009.08.049 ↗
20. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-210.1038/bjp.2008.260 ↗
21. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma10.1016/j.biomaterials.2011.02.044 ↗
22. Uptake and intracellular release kinetics of liposome formulations in glioma cells10.1016/j.ijpharm.2010.05.017 ↗
23. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(varepsilon-caprolactone) nanoparticles: in vitro and in vivo evaluation10.1016/j.ijpharm.2010.10.005 ↗
24. Fluvastatin stabilizes the blood-brain barrier in vitro by nitric oxide-dependent dephosphorylation of myosin light chains10.1016/j.neuropharm.2006.06.004 ↗
25. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells10.1158/0008-5472.CAN-08-0014 ↗
26. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
27. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma10.1016/j.biomaterials.2011.05.064 ↗